Yuyu Pharma enrols first patient in YP-P10 phase two clinical study
21 July 2022 -

Yuyu Pharma, a global pharmaceutical company founded in Seoul, South Korea, announced on Wednesday that it has enroled the first patient in a phase two clinical study assessing YP-P10, a novel and patented synthetic peptide with anti-inflammatory and wound healing properties intended to treat patients with dry eye disease (DED).

The company has received approval from the United States Food and Drug Administration (FDA) for its Investigational New Drug Application (IND) for YP-P10 Ophthalmic Solution.

The approval enabled the company to start the phase two clinical study, named ICECAP (randomIzed plaCebo EffiCacy sAfety yP-p10), to assess the safety, tolerability, and efficacy of the product to help advance the treatment of patients with DED. The study is to be carried out in the United States at seven sites with 240 patients. The product has been developed by Yuyu Pharma R&D.